Federico Monaca

Federico Monaca

Auto-generated profile, based on publicly available information

Federico Monaca

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
FMFederico Monaca
Federico Monaca
MRMartín Igor Gómez-Randulfe Rodríguez
Martín Igor Gómez-Randulfe Rodríguez
GWGerard M. Malachy Walls
Gerard M. Malachy Walls
OCOrnella Cantale
Ornella Cantale
APAna Sofia de Freitas Matos Parreira
Ana Sofia de Freitas Matos Parreira
RCRaffaele Califano
Raffaele Califano

15 April 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
FMFederico Monaca
Federico Monaca
MRMartín Igor Gómez-Randulfe Rodríguez
Martín Igor Gómez-Randulfe Rodríguez
APAna Sofia de Freitas Matos Parreira
Ana Sofia de Freitas Matos Parreira
VLVito Longo
Vito Longo
DGDomenico Galetta
Domenico Galetta
RCRaffaele Califano
Raffaele Califano

14 April 2026 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
FMFederico Monaca
Federico Monaca
IGIgor Gomez-Randulfe
Igor Gomez-Randulfe
JTJavier Torres-Jiménez
Javier Torres-Jiménez
MAMuskan Agarwal
Muskan Agarwal
SLStephen V. Liu
Stephen V. Liu
RCRaffaele Califano
Raffaele Califano

16 October 2025 in Lung Cancer
Verified
Journal Article
Closed access
IGIgor Gomez-Randulfe
Igor Gomez-Randulfe
FMFederico Monaca
Federico Monaca
OCOrnella Cantale
Ornella Cantale
Maria Lucia RealeMaria Lucia Reale
Maria Lucia Reale
LMLoredana Mrak
Loredana Mrak
RCRaffaele Califano
Raffaele Califano

14 June 2026 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
FMFederico Monaca
Federico Monaca
RWRachel Woodford
Rachel Woodford
KJKroopa Joshi
Kroopa Joshi
FTFiona Thistlethwaite
Fiona Thistlethwaite
KLKok Haw Jonathan Lim
Kok Haw Jonathan Lim
MRMartín Igor Gómez-Randulfe Rodríguez
Martín Igor Gómez-Randulfe Rodríguez
Cytokine release syndrome (CRS) represents a spectrum of immune hyperactivation initiated by rapid T-cell engagement and amplified through innate immune cells, particularly monocytes and macrophages, with downstream cytokine cascades driving endothelial dysfunction, capillary leak and organ impairment. CRS is a frequent, class-associated toxicity of T-cell-engaging immunotherapies and is being observed with increasing regularity as T-cell-redirecting therapies progress through clinical development in solid tumours. Although CRS is typically less severe in patients with solid tumours relative to those with haematological malignancies, phase II–III trials of these emerging agents consistently report grade 1–2 CRS in the majority of patients, highlighting the need for effective prevention and management strategies, while preserving anti-tumour activity of the primary therapy. Current grading and management algorithms have been largely extrapolated from experience with chimeric antigen receptor T-cell therapies and rely on step-up dosing, premedication, supportive care and escalation to interleukin (IL)-6/IL-6R blockade and corticosteroids. However, steroid-refractory or high-grade CRS, as well as overlapping syndromes underscore the limitations of this approach and the need for mechanism-based interventions targeting upstream mediators and signalling hubs. These include IL-1 blockade, Janus kinase-signal transducer and activator of transcription inhibition, granulocyte–macrophage colony-stimulating factor neutralisation, tumour necrosis factor-alpha inhibition and interferon gamma blockade. In this narrative review, we synthesise the mechanistic rationale and emerging clinical evidence underpinning CRS prevention and management in solid tumours, with a particular focus on T-cell engager (TCE) and other T-cell-redirecting therapies. We then outline key risk-mitigation strategies and discuss their potential implications for anti-tumour immunity. Finally, we highlight key knowledge gaps, particularly the paucity of prospective solid tumour-specific data, with current CRS prevention and management strategies therefore remaining largely extrapolated from haematological malignancies, alongside the need for biomarker-driven risk stratification, optimal sequencing and prophylactic strategies and the development of next-generation TCE designs.

1 September 2025 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
FMFederico Monaca
Federico Monaca
IGIgor Gómez-Randulfe
Igor Gómez-Randulfe
RCRaffaele Califano
Raffaele Califano
NY-ESO-1 targeting in non-small cell lung cancer: promise and challenges of letetresgene autoleucel